You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The company hopes the collaboration will allow it to home in on a molecularly defined population of patients likely to benefit from its targeted agent LP-184.
The company's approach combines whole-genome sequencing, CRISPR, liquid biopsy, and gene therapy to target cancer cells with gene fusions.
Genomic and epigenomic data suggest it may be possible to target an FGFR fusion found in open chromatin in a subset of adenosquamous carcinoma of the pancreas tumors.
Adult participants will have access to saliva-based testing from Invitae for the Screen Project, which aims to find clinically actionable BRCA1/2 mutations.
The collaboration seeks to develop RNA-based signatures that could help oncologists predict disease progression and guide the use of precision therapies.
Based on the expression of S100A2 and S100A4 proteins, researchers predicted which patients were likely to experience poor outcomes and disease recurrence post-surgery.
The approval will make Merck and AstraZeneca's Lynparza available to patients in the EU who have not progressed after 16 weeks on platinum-based chemotherapy.
The bioinformatics vendor is customizing a multiomics health data platform to help pancreatic cancer researchers pursue new therapeutic targets.
The agency based its decision on the results of the POLO trial, in which patients on olaparib had a median progression-free survival of 7.4 months compared to 3.8 months on placebo.
A more accurate, integrated risk model for pancreatic cancer included not only clinical risk factors, but also blood markers and pancreatic cancer loci from genome-wide association studies.